NCT03410693 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT03410693
Title	Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma (FORT-1)
Acronym	FORT-1
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	Bayer
Indications	ureter transitional cell carcinoma bladder urothelial carcinoma renal pelvis transitional cell carcinoma urethra transitional cell carcinoma
Therapies	Docetaxel Vinflunine Paclitaxel Rogaratinib
Age Groups:	senior \| adult
Covered Countries	USA \| SWE \| SVK \| POL \| NLD \| ITA \| ISR \| IRL \| HUN \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CHE \| CAN \| BEL \| AUT \| AUS

Additional content available in CKB BOOST